Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Clin Gastroenterol Hepatol ; 19(10): 2046-2053.e2, 2021 10.
Artigo em Inglês | MEDLINE | ID: mdl-32798708

RESUMO

BACKGROUND & AIMS: Based on histologic features, variants in STAT6 are associated with a poor initial response to proton pump inhibitor (PPI) therapy in pediatric patients with eosinophilic esophagitis (EoE). We investigated whether these genetic variants are associated with a poor long-term response in children with EoE who initially responded to PPI therapy. METHODS: We performed a prospective longitudinal cohort study of children ages 2 to 16 years who met the diagnostic criteria for EoE (≥15 eosinophils/high-power field [eos/hpf]), responded to 8 weeks of treatment with 2 mg/kg/d PPI (<15 eos/hpf), and whose dose then was reduced to 1 mg/kg/d PPI (maintenance therapy) for 1 year, at which point biopsy specimens were collected by endoscopy. Genomic DNA was isolated from formalin-fixed paraffin-embedded biopsy tissue and was genotyped for variants of STAT6. Remission of inflammation was assessed at eos/hpf thresholds of <15 and ≤5. RESULTS: Among 73 patients who received 1 mg/kg/d PPI maintenance therapy for 1 year, 13 patients (18%) had 6 to 14 eos/hpf, 36 patients (49%) had 5 or fewer eos/hpf, and 24 patients (33%) relapsed to EoE (≥15 eos/hpf). Carriage of any of 3 STAT6 variants in linkage disequilibrium (r2 ≥0.8; rs324011, rs167769, or rs12368672) was associated with a 2.3- to 2.8-fold increase in the odds of EoE relapse, and with a 2.8- to 4.1-fold increase in the odds of having 6 to 14 eos/hpf. For rs324011, the odds ratio [95% CI] for relapse was 2.77 [1.11, 6.92]; P = .029, and the odds ratio [95% CI] for having 6 to 14 eos/hpf was 3.06 [1.27, 7.36]; P = .012. CONCLUSIONS: Pediatric EoE patients who initially respond to PPI therapy and carry STAT6 variants rs324011, rs167769, or rs12368672 are at increased risk of relapse after 1 year of PPI maintenance therapy.


Assuntos
Esofagite Eosinofílica , Inibidores da Bomba de Prótons , Adolescente , Criança , Pré-Escolar , Esofagite Eosinofílica/tratamento farmacológico , Esofagite Eosinofílica/genética , Humanos , Estudos Longitudinais , Estudos Prospectivos , Inibidores da Bomba de Prótons/uso terapêutico , Recidiva , Fator de Transcrição STAT6/genética
2.
J Pediatr Gastroenterol Nutr ; 71(6): 755-763, 2020 12.
Artigo em Inglês | MEDLINE | ID: mdl-33003164

RESUMO

OBJECTIVES: Eosinophilic esophagitis (EoE) is a chronic esophageal disease characterized by eosinophilic inflammation. Proton-pump inhibitors (PPI) induce disease remission but no predictive factors of PPI-responsiveness have been identified yet. So, a biomarker must be found to differentiate between responders (PPI-R) and nonresponder patients (PPI-NR) to PPI. Aims were to identify any molecular biomarker that could predict PPI responsiveness and to study molecular remission after PPI therapy. METHODS: This prospective study enrolled 39 controls and 43 pediatric children with EoE from 2 hospitals, and they were treated with esomeprazole for 8 to 12 weeks. After therapy, patients were classified as either PPI-R or PPI-NR. Biopsies were collected and RNA, microRNAs, and proteins were isolated from them, measuring levels by qPCR and Western blot (WB). Also, miRNAs were evaluated in serum. RESULTS: We found several esophageal miRNAs with different expression values between PPI-R and PPI-NR children, which can be used to discriminate them (area under curve = 0.90). No useful serum miRNAs were, however, identified. Also, these miRNAs were dysregulated in responder patients before and after PPI therapy. Moreover, we corroborated in this child population, that PPI-R displayed a significant decrease in eotaxin-3, IL-5, IL-13, periostin, and major basic protein (P < 0.05) and a significant increase in filaggrin levels after PPI treatment (P < 0.01). CONCLUSIONS: Esophageal miRNA levels found are able to discriminate between both PPI-R and PPI-NR at baseline, and before and after treatment in PPI-R, so they could be used as biomarkers. Furthermore, we observed clinical and esophageal molecular restoration in PPI-R patients after PPI therapy.


Assuntos
Esofagite Eosinofílica , MicroRNAs , Inibidores da Bomba de Prótons , Biomarcadores/análise , Criança , Esofagite Eosinofílica/tratamento farmacológico , Esofagite Eosinofílica/genética , Proteínas Filagrinas , Humanos , Masculino , MicroRNAs/metabolismo , Estudos Prospectivos , Inibidores da Bomba de Prótons/uso terapêutico
3.
J Pediatr Gastroenterol Nutr ; 68(3): 364-370, 2019 03.
Artigo em Inglês | MEDLINE | ID: mdl-30418411

RESUMO

OBJECTIVES: To perform long-term celiac disease (CD) screening in an HLA-DQ2 (+) cohort from the general population and to assess the influence of risk genotypes on its development. METHODS: In 2004, an HLA-DQ2 (+) cohort was selected. After the first CD screening at age 2 to 3 years, we performed a follow-up screening 8 to 10 years later. Antitransglutaminase 2 antibodies were determined using a rapid test kit. Results were confirmed by serum IgA antitransglutaminase 2 and IgA endomysial antibody determination. CD diagnosis was carried out by intestinal biopsies. Four HLA-DQ2 genotypic groups were used: G1: DQ2.5/DQ2.5 (G1A) or DQ2.5/ DQ2.2 (G1B); G2: DQ2.2/DQ7.5 (DQ2.5 trans); G3: DQ2.5/ X; G4: DQ2.2/X. RESULTS: CD prevalence after 10 years of follow-up was 5.8% (95% confidence interval 3.8-8.7). One of every 3 HLA-DQ2(+) children carried at least 1 haplotype DQ2.2 or DQ7. The homozygous genotype DQ2.5/DQ2.5 and the HLA-DQ2.5 trans genotype increased CD risk 4- and 3-fold, respectively. The homozygous genotype DQ2.5/ DQ2.2 did not increase the CD risk. Children carrying G1 or G2 genotypes were diagnosed with CD earlier and more frequently during the follow-up compare with those carrying G3 or G4 genotypes. Approximately 81% of children with spontaneous antibody negativization after the first screening maintained negative antibodies. CONCLUSIONS: A repeated screening of at-risk children during their follow-up allowed us to diagnose new CD cases. In our cohort, HLA- DQ2.5 trans genotype conferred a higher risk in the development of CD than HLA- DQ2.5/DQ2.2. The majority of children with potential CD and CD autoimmunity at 10 years of age remained healthy.


Assuntos
Doença Celíaca/diagnóstico , Predisposição Genética para Doença/epidemiologia , Doença Celíaca/epidemiologia , Doença Celíaca/genética , Criança , Pré-Escolar , Feminino , Seguimentos , Testes Genéticos , Genótipo , Antígenos HLA-DQ/genética , Haplótipos , Humanos , Estudos Longitudinais , Masculino , Prevalência , Estudos Prospectivos , Fatores de Risco , Espanha
4.
J Pediatr Gastroenterol Nutr ; 67(2): 210-216, 2018 08.
Artigo em Inglês | MEDLINE | ID: mdl-29509636

RESUMO

OBJECTIVES: Proton pump inhibitor (PPI)-responsive eosinophilic esophagitis (EoE) is frequently observed in children, but data on long-term treatment are scarce. The objective of this study is to evaluate the long-term efficacy and safety of PPIs in children with EoE. METHODS: This prospective study enrolled children with EoE and histological remission to an 8-week esomeprazole trial (1 mg/kg/dose, twice daily). Esomeprazole was maintained at 1 mg/kg/day for 1 year. Symptom recurrence and adverse events were monitored and a follow-up endoscopy was performed at 12 months. Complete histological remission was defined as ≤5 eosinophils/high-power field (eos/hpf), and partial histological remission as >5 and <15 eos/hpf. Patients had no concomitant dietary restrictions or topical steroid. RESULTS: Fifty-seven children were included. Histological remission on maintenance PPI therapy was present in 40 children (70.1%; 95% CI 56.5-81.5). Long-term remission rate was higher in children with initial complete histological remission than in those with partial remission (81% vs 50%, P = 0.014). Forty-nine children (86%) remained asymptomatic. Pretreatment clinical and histological findings and median PPI dose/kg/day were similar between relapsers and nonrelapsers. Eleven out of 12 children (91.6%) receiving esomeprazole 0.5 mg ·â€Škg ·â€Š day for 12 additional months remained in remission. Mild and transient side effects without requiring PPI avoidance were observed in 5 children. CONCLUSIONS: Up to 70% of children with PPI-responsive EoE remain in histological and clinical remission on a low-dose maintenance treatment at 1-year follow-up, with adequate safety profile. Complete histological remission to an 8-week PPI trial was associated with higher probability of histological remission on maintenance therapy.


Assuntos
Esofagite Eosinofílica/tratamento farmacológico , Esomeprazol/uso terapêutico , Inibidores da Bomba de Prótons/uso terapêutico , Administração Oral , Adolescente , Criança , Serviços de Saúde da Criança , Pré-Escolar , Esquema de Medicação , Esofagite Eosinofílica/patologia , Esomeprazol/administração & dosagem , Esofagoscopia , Feminino , Humanos , Lactente , Masculino , Estudos Prospectivos , Inibidores da Bomba de Prótons/administração & dosagem , Recidiva , Indução de Remissão , Espanha , Resultado do Tratamento
5.
Pediatr Infect Dis J ; 32(8): 916-9, 2013 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-23624431

RESUMO

We present a prospective study of influenza C virus infections in hospitalized children in Spain during 6 years, including the pandemic influenza A (H1N1) pdm. Influenza C infections accounted for 13.3% of influenza-positive cases. The patients with simple influenza C infection were clinically similar to other influenza types, but a high rate of coinfection (81%) makes it difficult to assess its clinical role.


Assuntos
Gammainfluenzavirus/isolamento & purificação , Influenza Humana/terapia , Influenza Humana/virologia , Pré-Escolar , Feminino , Hospitalização/estatística & dados numéricos , Humanos , Lactente , Vírus da Influenza A Subtipo H1N1/isolamento & purificação , Vírus da Influenza B/isolamento & purificação , Influenza Humana/epidemiologia , Tempo de Internação , Masculino , Estudos Prospectivos , Espanha/epidemiologia , Estatísticas não Paramétricas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...